ClinicalTrials.gg
SuspendedNCT07219303DE-CARTUpdated Oct 29, 2026

Adaptive Radiation Therapy for Men With Intermediate- or High-Risk Prostate Cancer

An interventional study of adaptive stereotactic body radiation therapy (SBRT) with a SIB in Prostate Cancer (Adenocarcinoma), sponsored by Fox Chase Cancer Center. Suspended at 1 site in United States. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Fox Chase Cancer Center · Not applicable, Interventional, and Treatment

How we know

Why this study was suspended
Pending interim analysis
Updated Oct 29, 2026Now SuspendedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Not applicable
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center — none open to participants now, none under way, none of them phase 3. Prostatic Neoplasms · Fox Chase Cancer Center.

Planned enrollment
8th of 13
80 · median 116
Started
2025
the only one that year
No phase
7 of 14
none open now
Registered
14th of 14
by date

Among the 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center, this one is the 8th largest by planned enrollment of the 13 interventional ones that give a count, is the only one that started in 2025, is one of 7 with no phase, and was the 14th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

None of the 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center is open now. The open studies under Prostatic Neoplasms, anywhere →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 14 studies in Prostatic Neoplasms by Fox Chase Cancer Center as a file.
02

Study summary

The goal of this clinical trial is to evaluate if adaptive stereotactic body radiation therapy (SBRT) is a safe and effective way to treat prostate cancer in adults. It will assess the safety profile of adaptive SBRT over time.

The main questions this trial aims to answer are:

  • What is highest dose of adaptive SBRT without causing serious side effects?
  • Can adaptive SBRT more precisely targeting the prostate while reducing radiation exposure to nearby organs?
  • What side effects do participants experience during treatment, right after treatment, and over the five years post-treatment?
  • Can adaptive SBRT reduce urination-related side effects and support quality of life during and after treatment?

Participants will:

  • Receive adaptive SBRT treatment every other day, for a total of 5 treatment sessions (called fractions). The full course of treatment typically takes 2 to 3 weeks.
  • Have a follow-up phone call about 6 weeks after treatment to check on side effects and overall wellbeing.
  • Visit the clinic for check-ups and tests:

    • At 90 days (about 3 months) after treatment
    • Then every 3 months for the first year
    • Then every 6 months after that
03

Conditions studied

  • Prostate Cancer (Adenocarcinoma)

Keywords

  • Adaptive
  • SBRT
  • Stereotactic body radiation therapy
  • QOL
  • Simultaneous integrated boost
  • SIB
  • Adenocarcinoma
  • Prostate Cancer
  • Prostate Neoplasms
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Subjects must have confirmed intermediate- and favorable high risk (AJCC 8th ed stage IIA-IIC) adenocarcinoma of the prostate.
  2. Age > 18 years.
  3. performance status ≤ 2
  4. Prostate volume (segmented) ≤ 100 cc determined by MRI and/or US within 24 mo of treatment for patients not on ADT and within 6 mo for patients on prior ADT. A simulation MRI is acceptable.
  5. Subjects must have had a pre-treatment diagnostic multiparametric MRI prostate (mpMRI) showing a PI-RADS3, 4 or 5 lesion or a 68Ga- or 18F-PSMA (TLX591-CDx or piflufolastat F18) PET/CT within 12 mo of study registration.
  6. Baseline International Prostate Symptom Score (IPSS) is ≤ 15. Baseline alpha blocker use is allowed.
  7. Subjects must have full capacity to understand and be willing to sign the document.

Exclusion criteria

Exclusion Criteria:

  1. Subjects must not be experiencing toxicity grade ≥ 3 GU or GI toxicity at baseline.
  2. Subjects must not be receiving any other agents.
  3. Subjects must not have had prior pelvic radiation therapy.
  4. Subjects must not have node-positive disease.
  5. Subjects must not have extraprostatic extension determined by MRI prostate within 24 mo of treatment. For patients receiving ADT, the prostate MRI must have been obtained prior to the start of ADT.
  6. Subjects must not have had prior ablative therapies for prostate cancer including cryosurgery, HIFU and nanoknife.
  7. Subjects with prior TURP or laser enucleation are eligible. However, patients that have undergone prior simple prostatectomy are excluded.
  8. Subjects that are receiving other antineoplastic agents including methotrexate are ineligible. Subjects that have received prior ADT are eligible if they have received \< 6 mo total of ADT, if last administration of ADT was > 6 mo prior to registration and serum total testosterone levels have recovered to at least 100 ng/dL. Subjects with prior cancer diagnoses are eligible provided that treatment was completed and no evidence of disease status achieved at least 2 years prior to study registration.
  9. Subjects must not have uncontrolled intercurrent illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
  10. Any condition or significant co-morbidity that prevents safe delivery of SBRT per the discretion of the treating physician(s).
  11. Subjects with active inflammatory bowel disease or active collagen vascular disorder.
  12. Subjects that cannot undergo prostate fiducial placement.
  13. Subjects that cannot undergo rectal spacer placement are excluded. Please, note that a rectal spacer incorporating iodine or similar CT contrast is preferred. However, patients that are able to only have a non-contrast rectal spacer due to iodine allergy or similar remain eligible.
  14. Subjects that cannot undergo prostate MRI.
  15. Subjects with bilateral prosthetic hips will be excluded. Subjects with unilateral prosthetic hips will be eligible only if the initial treatment plan meets all target and normal tissue constraints without protocol violation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Phase I Dose escalated adaptive stereotactic body radiation therapy (SBRT) with a SIB

    Radiation: adaptive stereotactic body radiation therapy (SBRT) with a SIB

Interventions

  • Radiationadaptive stereotactic body radiation therapy (SBRT) with a SIB

    This is a phase 1 dose finding study investigating escalated doses of adaptive prostate SBRT for patients with intermediate and favorable high risk prostate cancer. There will be a Bayseian Optimal Interval Design (BOIN) defining the dose escalation parameters and the dose will escalate as per Section 5.0. Treatment is 5 fractions every other day and will be expected to be typically completed in 2-3 calendar weeks.

06

What researchers measure

Primary outcomes

  1. Severe (CTCAE grade ≥ 3) treatment-related (possibly, probably or definitely) toxicity occurring within 90 days of treatment.

    Time frame: From initiation of treatment to 90 days after end of treatment, for a duration of ~100 days.

Secondary outcomes

  1. Biochemically progression free survival

    Time from the end of treatment administration to biochemical progression (using Pheonix definition), local, regional, or distant progression, initiation of additional prostate cancer therapy, or death. Patients who are alive and have not experienced any progression or initiated any additional prostate cancer therapy by the end of follow up are considered censored.

    Time frame: From end of treatment to biochemical, local, regional or distant progression, or initiation of additional prostate cancer therapy or death, or end of follow up for a total of up to 5 years.

  2. Local failure free survival

    Time from the end of treatment administration to local progression or death. Patients who are still alive and have not had local progression by the end of follow up are considered censored.

    Time frame: From end of treatment to local progression or death or end of follow up for a total of up to 5 years.

  3. PSA response

    The PSA response will be assessed by the post-treatment PSA nadir and time to nadir.

    Time frame: From end of treatment to end of follow-up for a total of up to 5 years.

  4. The proportion of patients who have a decrease greater than or equal to the acute minimum clinically important difference (MID) in EPIC-26 scores among the urinary, bowel and sexual function domains at 3 and 6 months post-treatment compared to baseline

    Time frame: From enrollment to 6 months post-treatment.

  5. The proportion of patients who have a decrease greater than or equal to the minimum clinically important difference (MID) in EPIC-26 scores among the urinary, bowel and sexual function domains at 1 and 2 years post-treatment compared to baseline.

    Time frame: From enrollment to 2 years post-treatment for a duration of ~ 2.5 years.

  6. Distant metastasis free survival

    Time from the end of treatment administration to distant metastasis or death. Patients who are still alive and metastasis-free at the end of follow up are considered censored.

    Time frame: From end of treatment to distant metastasis or death or end of follow up, for a total of up to 5 years.

  7. The proportion of patients who had at least one optimal treatment planning criteria not met, the number of criteria not met per patient, and the number of criteria not met per organ site.

    These proportions will be assessed in the overall population and per dose level.

    Time frame: From radiation simulation to end of treatment for a duration of 2-3 months.

07

Study locations

1 site
  • Fox Chase Cancer Center
    Philadelphia, Pennsylvania 19111, United States
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2025 (actual). Primary completion is estimated for Aug 2033, 94 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 16, 2025
First posted
Oct 21, 2025
StartActual
Sep 25, 2025
Primary completionEst.
Aug 1, 2033
CompletionEst.
Nov 1, 2033
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Suspended Pending interim analysis
changed Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Recruiting→Suspended
    Why stopped Pending interim analysis
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07219303
Responsible party
Sponsor
First posted
Oct 21, 2025
Start date
Sep 25, 2025
Primary completion
Aug 1, 2033 (estimated)
Completion
Nov 1, 2033 (estimated)
Last update
Oct 29, 2026

Study contacts

Mark A Hallman, MD, PhD
principal investigator · FCCC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion